???global.info.a_carregar???
I obtained my PhD in Human Biology in 2010 from the University of Porto. From 2011 to 2013, I was a postdoctoral researcher in Dr. Haigis’ lab at Massachusetts General Hospital/Harvard Medical School, USA. Since 2014, I have been an independent researcher at i3S/IPATIMUP, leading a research line on tumor microenvironment interactions and KRAS oncogenic signaling. During this time, I also became a mother of three children (2012, 2017, 2020). My h-index is 24 (Google Scholar), with over 3,000 citations, reflecting the impact of my work. I have published 38 papers in international journals, including the Journal of Clinical Oncology, Cancer Discovery, Gastroenterology, Cancer Research, and Oncogene, with more than 70% in Q1 journals, and 7 book chapters (5 as senior author). RESEARCH CONTRIBUTIONS & EXPERTIZE During my PhD, I characterized gastrointestinal cancers, focusing on alterations in the KRAS-MAPK and PI3K pathways. I was the first to describe and functionally characterize MLK3 mutations in gastrointestinal cancers, demonstrating that different cancer subtypes not only harbor distinct driver mutations but also show variability within the same gene. As a postdoc, I worked on the functional characterization of RAS mutations in colorectal cancer, gaining expertise in in vitro and in vivo models, which remain central to my current research. Since establishing my independent research group in 2014, I have focused on the crosstalk between cancer cells and the tumor microenvironment, particularly fibroblasts and immune cells, and how KRAS oncogenic signaling influences these interactions, disease progression, and therapy resistance. I am also engaged in novel therapy development and drug repurposing for cancer treatment. As an independent researcher, I have published 7 papers as senior author, 12 collaborative papers, and 4 book chapters. My team’s work has been recognized with several research awards. I have also participated in technology transfer and entrepreneurship programs to translate fundamental research into therapeutic applications. SUPERVISION & MENTORSHIP Since 2014, I have supervised: 2 junior students 1 visiting MSc student 10 MSc students 3 international visiting students (2 PhD, 1 BSc) 3 research fellows, all currently pursuing PhDs under my supervision Currently, I am the main supervisor of 4 PhD students and the co-supervisor of 2 PhD students and 3 MSc students. FUNDING & COLLABORATIONS Since 2014, I have secured €753K in salary grants and €591K in research funding, including: €434K as PI (4 project grants) €95K as co-PI (2 projects) €62K as co-investigator (3 projects) I have established a multidisciplinary and international network of collaborators, encompassing life sciences, chemistry, pharmacology, and clinical research, to support and enhance my research activities. SCIENTIFIC RECOGNITION & LEADERSHIP My work has been nationally and internationally recognized through: 8 invited and 3 selected presentations at scientific meetings Peer review for over 20 renowned journals and 5 funding agencies Participation in 14 scientific juries Guest-editing 2 special issues in Cells and 1 in International Journal of Molecular Sciences Editorial role at Frontiers in Gastroenterology (Gastroenterology and Cancer section) Additionally, I served on the scientific committee for one national and one international conference and am currently co-organizing the SINAL international meeting.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Sérgia Velho
Género
Feminino

Nomes de citação

  • VELHO, SERGIA

Identificadores de autor

Ciência ID
B316-B47C-2855
ORCID iD
0000-0002-7104-8234
Google Scholar ID
qmAvPh0AAAAJ&hl
Scopus Author Id
8738558400

Endereços de correio eletrónico

  • svelho@ipatimup.pt (Profissional)

Telefones

Telefone
  • 226074900 (Profissional)

Moradas

  • Rua Alfredo Allen, 208, 4200-135, Porto, Porto, Portugal (Profissional)

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Clínica - Oncologia

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Alemão Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1)
Espanhol; Castelhano Utilizador elementar (A1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador elementar (A1)
Formação
Grau Classificação
2006 - 2010
Concluído
 Human Biology (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
"The role of BRAF and KRAS activating mutations in deficient and proficient MMR colorectal carcinomas." (TESE/DISSERTAÇÃO)
 Approved
1999 - 2003
Concluído
 Biology (Licenciatura)
Universidade do Porto Faculdade de Ciências, Portugal
"Screening of germline mutations in members of the ERM family in HDGC." (TESE/DISSERTAÇÃO)
 15
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2022 - Atual Investigador Auxiliar (carreira) (Investigação) Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal
2014 - 2019 Investigador Auxiliar (carreira) (Investigação) Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
2011 - 2013 Pós-doutorado (Investigação) Harvard Medical School, Estados Unidos

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento 		Empregador
2017 - 2019 Professor Adjunto Convidado (Docente Ensino Superior Politécnico) Instituto Politécnico do Porto Escola Superior de Saúde, Portugal
2017 - 2018 Assistente convidado (Docente Ensino Superior Politécnico) Instituto Politécnico do Porto, Portugal

Cargos e Funções

Categoria Profissional
Instituição de acolhimento 		Empregador
2023 - 2025 Honorary Collaborator Universidad de Valladolid, Espanha
2019 - 2021 Junior Researcher Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
2006 - 2010 PhD student Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
Projetos

Projeto

Designação Financiadores
2023/02/01 - 2024/07/31 Novos biomarcadores fecais para deteção precoce de lesões pré-malignas e cancro: Otimização do modelo atual de rastreio em cancro colorretal
2022.09051.PTDC
10.54499/2022.09051.PTDC
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto de Astrofísica e Ciências do Espaço, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2023/01/01 - 2024/06/30 Deconstructing the Cell Communication Routes of mutant KRAS Colorectal Liver to Lung Metastasis: improving patient survival
2022.05346.PTDC
10.54499/2022.05346.PTDC
Research team member
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Instituto Português de Oncologia de Coimbra Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2018/10/15 - 2021/10/14 MAGICIAM: um sistema imunomodelador de macrófagos para prevenir a invasão e metastização das células tumorais
PTDC/BTM-SAL/31859/2017
Instituto Nacional de Engenharia Biomédica, Portugal

Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal

Associação para a Investigação e Desenvolvimento da Faculdade de Medicina, Portugal

Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2017/01/01 - 2021/03/31 Estaminalidade das células do cancro: um desafio e uma oportunidade para avançar no tratamento em Oncologia
SAICTPAC/0022/2015
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Instituto Nacional de Engenharia Biomédica, Portugal

Fundação Calouste Gulbenkian, Portugal

Universidade de Coimbra, Portugal

Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2019 - 2021 MAGICIAM: a MAcrophaGe Immunomodulatory-delivery system to prevent Cancer Invasion And Metastasis
POCI-01-0145-FEDER-031859
Investigador
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2018 - 2021 Pre-clinical evaluation of novel chemical compounds for cancer treatment: tackling unmet clinical needs
POCI-01-0145-FEDER-031354
Investigador responsável
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2018 - 2019 Influence of an optimized combined dietary and exercise intervention on cytokine profile and NK cell infiltration of the tumor: an exploratory pilot study
Investigador
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Sociedade Portuguesa de Gastroenterologia
Concluído
2017 - 2019 Tackling CANcer STEM CELls: a challenge and an opportunity to advance in anti¬cancer therapy
POCI-01-0145-FEDER-016390
Investigador responsável
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal

Instituto de Medicina Molecular, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2016 - 2019 Advancing cancer research: from basic knowledge to application
NORTE-01-0145-FEDER-000029
Investigador responsável
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 N2020 program
Concluído
2017 - 2018 OncoAdvanC+: Bringing new solutions for cancer therapy
Investigador responsável
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 RESOLVE program
Concluído
2014 - 2018 Epithelial stromal crosstalk as a major driver of colorectal cancer development and progression: an approach to identify its master regulators
IF/00136/2013/CP1184/CT0003
Investigador responsável
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Concluído
2015 - 2016 Mesenchymal stem cells in inflamatory bowel disease: therapeutic strategy or cancer promoters?
.
Investigador responsável
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 GEDII
2013 - 2015 Functional Significance of E-cadherin Germline Missense Mutations in Diffuse Gastric Cancer
POCTI/CBO/44849/2002
Investigador
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Concluído
2013 - 2015 Molecular mechanisms underlying cancer cell invasion in two cancer disease models, gastric and breast
Investigador
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
Concluído
2011/01/01 - 2012/12/31 Projecto Estratégico - LA 3 - 2011-2012
PEst-C/SAU/LA0003/2011
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Concluído
2008 - 2011 MLK3, a new mutated gene in MSI colorectal cancer
grant.Provided by PTCRIS: 68310
PTDC/SAU-OBD/68310/2006
Investigador
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Concluído
2005 - 2008 In mismatch repair deficiency colorectal cancer are BRAF and KRAS new prognostic and therapeutic tools?
grant.Provided by PTCRIS: 56921
POCI/SAU-OBS/56921/2004
Investigador
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Concluído
Produções

Publicações

Artigo em revista
  1. Oliveira, Susana Mendonça; Carvalho, Patrícia Dias; Serra-Roma, André; Oliveira, Patrícia; Ribeiro, Andreia; Carvalho, Joana; Martins, Flávia; et al. "Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells". Cancers 16 14 (2024): 2595. https://doi.org/10.3390/cancers16142595.
    Publicado • 10.3390/cancers16142595
  2. Marques, Ana Camila; Costa, Paulo C.; Velho, Sérgia; Amaral, Maria Helena. "Rheological and Injectability Evaluation of Sterilized Poloxamer-407-Based Hydrogels Containing Docetaxel-Loaded Lipid Nanoparticles". Gels 10 5 (2024): 307. https://doi.org/10.3390/gels10050307.
    10.3390/gels10050307
  3. Marques, Ana; Costa, Paulo; Velho, Sérgia; Amaral, Maria. "Analytical Techniques for Characterizing Tumor-Targeted Antibody-Functionalized Nanoparticles". Life 14 4 (2024): 489. https://doi.org/10.3390/life14040489.
    10.3390/life14040489
  4. Marques, Ana Camila; Costa, Paulo Cardoso; Velho, Sérgia; Amaral, Maria Helena. "Injectable Poloxamer Hydrogels for Local Cancer Therapy". Gels 9 7 (2023): 593. http://dx.doi.org/10.3390/gels9070593.
    Publicado • 10.3390/gels9070593
  5. Martins, Flavia; Machado, Ana L.; Carvalho, Patricia D.; Carvalho, Joana; Matthiesen, Rune; Backman, Vadim; Velho, Sergia. "Abstract A006: Chromatin remodeling as a potential epigenetic mechanism of tolerance to KRAS loss". Molecular Cancer Research 21 5_Suppleme (2023): A006-A006. http://dx.doi.org/10.1158/1557-3125.ras23-a006.
    Publicado • 10.1158/1557-3125.ras23-a006
  6. Marques, Ana Camila; Costa, Paulo C.; Velho, Sérgia; Amaral, Maria Helena. "Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy". Pharmaceutics 15 1 (2023): 216. http://dx.doi.org/10.3390/pharmaceutics15010216.
    Publicado • 10.3390/pharmaceutics15010216
  7. Patrícia Dias Carvalho; Flávia Martins; Susana Mendonça; Andreia Ribeiro; Ana Luísa Machado; Joana Carvalho; Maria José Oliveira; Sérgia Velho. "Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis". International Journal of Cancer (2022): https://doi.org/10.1002/ijc.34225.
    10.1002/ijc.34225
  8. Dias Carvalho, Patrícia; Mendonça, Susana; Martins, Flávia; Oliveira, Maria José; Velho, Sérgia. "Modulation of Fibroblast Phenotype by Colorectal Cancer Cell-Secreted Factors Is Mostly Independent of Oncogenic KRAS". Cells 11 16 (2022): 2490. http://dx.doi.org/10.3390/cells11162490.
    Publicado • 10.3390/cells11162490
  9. Dias Carvalho, Patrícia; Martins, Flávia; Carvalho, Joana; Oliveira, Maria José; Velho, Sérgia. "Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors". Cells 11 13 (2022): 1988. http://dx.doi.org/10.3390/cells11131988.
    Publicado • 10.3390/cells11131988
  10. Marques-Magalhães, Ângela; Cruz, Tânia; Costa, Ângela Margarida; Estêvão, Diogo; Rios, Elisabete; Canão, Pedro Amoroso; Velho, Sérgia; et al. "Decellularized Colorectal Cancer Matrices as Bioactive Scaffolds for Studying Tumor-Stroma Interactions". Cancers 14 2 (2022): 359. http://dx.doi.org/10.3390/cancers14020359.
    Publicado • 10.3390/cancers14020359
  11. Marques, Ana C.; Costa, Paulo J.; Velho, Sérgia; Amaral, Maria H.. "Stimuli-responsive hydrogels for intratumoral drug delivery". Drug Discovery Today 26 10 (2021): 2397-2405. http://dx.doi.org/10.1016/j.drudis.2021.04.012.
    10.1016/j.drudis.2021.04.012
  12. Ana Patrícia Cardoso; Marta Laranjeiro Pinto; Flávia Castro; Ângela Margarida Costa; Ângela Marques-Magalhães; Ana Canha-Borges; Tânia Cruz; Sérgia Velho; Maria José Oliveira. "The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment". Cytokine & Growth Factor Reviews (2021): https://doi.org/10.1016/j.cytogfr.2021.03.005.
    10.1016/j.cytogfr.2021.03.005
  13. Varela-Calviño, Rubén; Rodríguez-Quiroga, Marta; Carvalho, Patrícia Dias; Martins, Flavia; Serra-Roma, André; Vázquez-Iglesias, Lorena; Cadena, María Páez; Velho, Sérgia; Cordero, Oscar J. "On the mechanism of sitagliptin inhibition of colorectal cancer cell lines’ metastatic functionalities". IUBMB Life (2021): http://dx.doi.org/10.1002/iub.2454.
    Publicado • 10.1002/iub.2454
  14. Marques, A.C.; Costa, P.J.; Velho, S.; Amaral, M.H.. "Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies". Journal of Controlled Release 320 (2020): 180-200. http://dx.doi.org/10.1016/j.jconrel.2020.01.035.
    Publicado
  15. Dias Carvalho, Patrícia; Machado, Ana Luísa; Martins, Flávia; Seruca, Raquel; Velho, Sérgia. "Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors". Cancers 11 12 (2019): 2010. http://dx.doi.org/10.3390/cancers11122010.
    Acesso aberto • Publicado
  16. Carneiro, Patrícia; Moreira, Ana Margarida; Figueiredo, Joana; Barros, Rita; Oliveira, Patrícia; Fernandes, Maria Sofia; Ferro, Anabela; et al. "S100P is a molecular determinant of E-cadherin function in gastric cancer". Cell Communication and Signaling 17 1 (2019): http://dx.doi.org/10.1186/s12964-019-0465-9.
    Acesso aberto • Publicado
  17. Carvalho, P.D.; Guimarães, C.F.; Cardoso, A.P.; Mendonça, S.; Costa, Â.M.; Oliveira, M.J.; Velho, S.. "KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment". Cancer Research 78 1 (2018): 7-14. http://www.scopus.com/inward/record.url?eid=2-s2.0-85040196244&partnerID=MN8TOARS.
    Publicado • 10.1158/0008-5472.CAN-17-2084
  18. Fernandes, Maria Sofia; Melo, Soraia; Velho, Sérgia; Carneiro, Patrícia; Carneiro, Fátima; Seruca, Raquel. "Specific inhibition of p110a subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers". Oncotarget 7 42 (2016): 68546-68558. http://dx.doi.org/10.18632/oncotarget.11843.
    Acesso aberto • Publicado • 10.18632/oncotarget.11843
  19. Pinto, Ana T.; Pinto, Marta L.; Velho, Sérgia; Pinto, Marta T.; Cardoso, Ana P.; Figueira, Rita; Monteiro, Armanda; et al. "Intricate Macrophage-Colorectal Cancer Cell Communication in Response to Radiation". PLOS ONE 11 8 (2016): e0160891. http://dx.doi.org/10.1371/journal.pone.0160891.
    Acesso aberto • Publicado • 10.1371/journal.pone.0160891
  20. Velho, S.; Pinto, A.; Licastro, D.; Oliveira, M.J.; Sousa, F.; Stupka, E.; Seruca, R.. "Dissecting the signaling pathways associated with the oncogenic activity of MLK3 P252H mutation". BMC Cancer 14 1 (2014): http://www.scopus.com/inward/record.url?eid=2-s2.0-84899084890&partnerID=MN8TOARS.
    10.1186/1471-2407-14-182
  21. Velho, S.; Fernes, M.S.; Leite, M.; Figueiredo, C.; Seruca, R.. "Causes and consequences of microsatellite instability in gastric carcinogenesis". World Journal of Gastroenterology 20 44 (2014): 16433-16442. http://www.scopus.com/inward/record.url?eid=2-s2.0-84918813931&partnerID=MN8TOARS.
    10.3748/wjg.v20.i44.16433
  22. Wang, Y.; Velho, S.; Vakiani, E.; Peng, S.; Bass, A.J.; Chu, G.C.; Gierut, J.; et al. "Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression". Cancer Discovery 3 3 (2013): 294-307. http://www.scopus.com/inward/record.url?eid=2-s2.0-84876064070&partnerID=MN8TOARS.
    Publicado • 10.1158/2159-8290.CD-12-0198
  23. Corso, G.; Velho, S.; Paredes, J.; Pedrazzani, C.; Martins, D.; Milanezi, F.; Pascale, V.; et al. "Oncogenic mutations in gastric cancer with microsatellite instability". European Journal of Cancer 47 3 (2011): 443-451. http://www.scopus.com/inward/record.url?eid=2-s2.0-79251593630&partnerID=MN8TOARS.
    10.1016/j.ejca.2010.09.008
  24. Velho, S.; Haigis, K.M.. "Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras". Experimental Cell Research 317 19 (2011): 2732-2739. http://www.scopus.com/inward/record.url?eid=2-s2.0-80455174751&partnerID=MN8TOARS.
    10.1016/j.yexcr.2011.06.002
  25. Velho, S.; Corso, G.; Oliveíra, C.; Seruca, R.. "KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers.". Advances in cancer research 109 (2010): 123-143. http://www.scopus.com/inward/record.url?eid=2-s2.0-79952278820&partnerID=MN8TOARS.
  26. Velho, S.; Oliveira, C.; Seruca, R.. "KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases". Journal of Clinical Oncology 27 1 (2009): 158-159. http://www.scopus.com/inward/record.url?eid=2-s2.0-58149327464&partnerID=MN8TOARS.
    10.1200/JCO.2008.20.1525
  27. Pedrazzani, C.; Corso, G.; Velho, S.; Leite, M.; Pascale, V.; Bettarini, F.; Marrelli, D.; Seruca, R.; Roviello, F.. "Evidence of tumor microsatellite instability in gastric cancer with familial aggregation". Familial Cancer 8 3 (2009): 215-220. http://www.scopus.com/inward/record.url?eid=2-s2.0-68449100164&partnerID=MN8TOARS.
    10.1007/s10689-008-9231-7
  28. Seruca, R.; Velho, S.; Oliveira, C.; Leite, M.; Matos, P.; Jordan, P.. "Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors". Expert Review of Gastroenterology and Hepatology 3 1 (2009): 5-9. http://www.scopus.com/inward/record.url?eid=2-s2.0-65549085862&partnerID=MN8TOARS.
    10.1586/17474124.3.1.5
  29. Velho, S.; Oliveira, C.; Paredes, J.; Sousa, S.; Leite, M.; Matos, P.; Milanezi, F.; et al. "Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours". Human Molecular Genetics 19 4 (2009): 697-706. http://www.scopus.com/inward/record.url?eid=2-s2.0-77950353937&partnerID=MN8TOARS.
    10.1093/hmg/ddp536
  30. Preto, A.; Figueiredo, J.; Velho, S.; Ribeiro, A.S.; Soares, P.; Oliveira, C.; Seruca, R.. "BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations". Journal of Pathology 214 3 (2008): 320-327. http://www.scopus.com/inward/record.url?eid=2-s2.0-38949208776&partnerID=MN8TOARS.
    10.1002/path.2295
  31. Matos, P.; Oliveira, C.; Velho, S.; Gonçalves, V.; da Costa, L.T.; Moyer, M.P.; Seruca, R.; Jordan, P.. "B-RafV600E Cooperates With Alternative Spliced Rac1b to Sustain Colorectal Cancer Cell Survival". Gastroenterology 135 3 (2008): 899-906. http://www.scopus.com/inward/record.url?eid=2-s2.0-51249098983&partnerID=MN8TOARS.
    10.1053/j.gastro.2008.05.052
  32. Velho, S.; Moutinho, C.; Cirnes, L.; Albuquerque, C.; Hamelin, R.; Schmitt, F.; Carneiro, F.; Oliveira, C.; Seruca, R.. "BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?". BMC Cancer 8 (2008): http://www.scopus.com/inward/record.url?eid=2-s2.0-53149097362&partnerID=MN8TOARS.
    10.1186/1471-2407-8-255
  33. Alazzouzi, H.; Suriano, G.; Guerra, A.; Plaja, A.; Espín, E.; Armengol, M.; Alhopuro, P.; et al. "Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells". Journal of Medical Genetics 44 1 (2007): 75-80. http://www.scopus.com/inward/record.url?eid=2-s2.0-33846443195&partnerID=MN8TOARS.
    10.1136/jmg.2006.042572
  34. Oliveira, C.; Velho, S.; Moutinho, C.; Ferreira, A.; Preto, A.; Domingo, E.; Capelinha, A.F.; et al. "KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression". Oncogene 26 1 (2007): 158-163. http://www.scopus.com/inward/record.url?eid=2-s2.0-33846048042&partnerID=MN8TOARS.
    10.1038/sj.onc.1209758
  35. Davalos, V.; Dopeso, H.; Velho, S.; Ferreira, A.M.; Cirnes, L.; Díaz-Chico, N.; Bilbao, C.; et al. "High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability". Oncogene 26 2 (2007): 308-311. http://www.scopus.com/inward/record.url?eid=2-s2.0-33846239265&partnerID=MN8TOARS.
    10.1038/sj.onc.1209780
  36. Meireles, A.M.; Preto, A.; Rocha, A.S.; Rebocho, A.P.; Máximo, V.; Pereira-Castro, I.; Moreira, S.; et al. "Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines". Thyroid 17 8 (2007): 707-715. http://www.scopus.com/inward/record.url?eid=2-s2.0-36649017735&partnerID=MN8TOARS.
    10.1089/thy.2007.0097
  37. Preto, A.; Moutinho, C.; Velho, S.; Oliveira, C.; Rebocho, A.P.; Figueiredo, J.; Soares, P.; Lopes, J.M.; Seruca, R.. "A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation". Virchows Archiv 450 6 (2007): 619-626. http://www.scopus.com/inward/record.url?eid=2-s2.0-34250805986&partnerID=MN8TOARS.
    10.1007/s00428-007-0420-9
  38. Velho, S.; Oliveira, C.; Ferreira, A.; Ferreira, A.C.; Suriano, G.; Schwartz Jr., S.; Duval, A.; et al. "The prevalence of PIK3CA mutations in gastric and colon cancer". European Journal of Cancer 41 11 (2005): 1649-1654. http://www.scopus.com/inward/record.url?eid=2-s2.0-22144452507&partnerID=MN8TOARS.
    10.1016/j.ejca.2005.04.022
  39. Oliveira, C.; Velho, S.; Domingo, E.; Preto, A.; Hofstra, R.M.W.; Hamelin, R.; Yamamoto, H.; Seruca, R.; Schwartz Jr., S.. "Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer". Oncogene 24 51 (2005): 7630-7634. http://www.scopus.com/inward/record.url?eid=2-s2.0-27844458489&partnerID=MN8TOARS.
    10.1038/sj.onc.1208906
  40. Oliveira, C.; Westra, J.L.; Arango, D.; Ollikainen, M.; Domingo, E.; Ferreira, A.; Velho, S.; et al. "Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status". Human Molecular Genetics 13 19 (2004): 2303-2311. http://www.scopus.com/inward/record.url?eid=2-s2.0-5444224121&partnerID=MN8TOARS.
    10.1093/hmg/ddh238
Capítulo de livro
  1. Ana Camila Marques; Paulo Cardoso da Costa; Sérgia Velho; Maria Helena Amaral. "Antibody-Functionalized Nanoparticles for Targeted Drug Delivery in Cancer Therapy". 2023.
    10.1007/978-3-030-80962-1_297-1
  2. VELHO, SERGIA. "Animal models to study cancer and its microenvironment". In Tumor Microenvironment The Main Driver of Metabolic Adaptation. Springer International Publishing, 2020.
    Aceite para publicação
  3. Carvalho, Patrícia; Roma, André; Velho, Sérgia. "Tracking cancer In vivo imaging techniques". In Fluorescence Imaging and Biological Quantification, 85-103. Boca Raton, Estados Unidos: CRC Press, 2017.
    Publicado
  4. Fernandes, MS; Seruca, R.; VELHO, SERGIA. "Microsatellite instability in colorectal cancer". In Molecular Pathology A Practical Guide for the Surgical Pathologist and Cytopathologist, 119-129. Cambridge, Reino Unido: Cambridge University Press, 2016.
    Publicado
  5. Corso, G.; Velho, S.. "Gastric cancer in other inherited syndromes". 2013.
    10.1007/978-94-007-6570-2_15
  6. Oliveira, M.J.; Velho, S.. "The association between inflammation and colorectal cancer". 2013.
    10.1007/978-1-4614-8412-7_3
  7. Velho, Sérgia; Oliveira, Carla; Seruca, Raquel. "PIK3CA Gene Alterations in Human Cancers". In Bioinformatics in Cancer and Cancer Therapy, 1-20. Humana Press, 2008.
    Publicado
Poster em conferência
  1. Machado, Ana Luísa; VELHO, SERGIA. "A Novel Approach to Colon Cancer Classification: cholesterol metabolism and its biological and clinical significance for immunotherapy". Trabalho apresentado em III ASPIC-ASEICA International Meeting – Cancer Immunology, Tumor Microenvironment and Metastasis, 2023.
  2. Carvalho, Patrícia Dias; Martins, Flávia; Susana Mendonça; Maria José Cardoso Oliveira (INEB,UP); VELHO, SERGIA. "KRAS-C-MET-HGF axis: an important modulator of fibroblast-induced colorectal cancer cell invasion". Trabalho apresentado em II ASPIC-ASEICA International Meeting – Current Trends in Precision Medicine in Cancer» (online event), 2021.
  3. Carvalho, Patrícia Dias; Martins, Flávia; Susana Mendonça; Maria José Cardoso Oliveira (INEB,UP); VELHO, SERGIA. "Eixo KRAS-C-MET-HGF: um importante modulador da invasão de células de cancro colorretal induzida por fibroblastos". Trabalho apresentado em 3º Encontro Nacional de Jovens Investigadores em Oncologia (ENJIO), 2021.
  4. Mendonça, S; Dias Carvalho, Patrícia; Roma, André; Ribeiro, Andreia; Martins, Flávia; Machado, Ana Luisa; Sousa, Bárbara; Oliveira, Maria José; VELHO, SERGIA. "Fibroblasts-secreted factors overcome KRAS inhibition inducing colorectal cancer stem cell properties". Trabalho apresentado em EACR 2021 Virtual Congress: Innovative Cancer Science, 2021.
  5. Carvalho, Patrícia Dias; Martins, Flávia; Susana Mendonça; Maria José Cardoso Oliveira (INEB,UP); VELHO, SERGIA. "Friend or foe: the different roles of oncogenic KRAS in fibroblast-induced colorectal cancer cell invasion". Trabalho apresentado em EACR 2021 Congress, Innovative Cancer Science: Better Outcomes through Research (Online event), 2021.
  6. Mendonça, S; Dias Carvalho, Patrícia; Roma, André; Ribeiro, Andreia; Martins, Flávia; Machado, Ana Luisa; Sousa, Bárbara; Oliveira, Maria José; VELHO, SERGIA. "Lifting the veil on resistance mechanisms to KRAS inhibition: Fibroblasts restore the cancer stemness potential lost upon KRAS silencing". Trabalho apresentado em 27th Porto Cancer Meeting - Stemness & Metastasis: Advances in Research and Clinical Translation, 2021.
  7. Martins, Flávia; Dias Carvalho, Patrícia; Carvalho, J; Matthiesen, R; VELHO, SERGIA. "2D versus 3D proteomic profile of oncogenic KRAS signaling". Trabalho apresentado em 3rd PhDay - Back to the Future, 2020.
  8. Mendonça, S; Dias Carvalho, P.; Cardoso, P; Martins, F; Ribeiro, A; Oliveira, Maria José; VELHO, SERGIA. "O papel dos fibroblastos na aquisição de propriedades estaminais nas células de cancro colorretal". Trabalho apresentado em 2º Encontro Nacional de Jovens Investigadores em Oncologia, 2020.
  9. Dias Carvalho, Patrícia; Martins, Flávia; Mendonça, S; Maria José Oliveira; VELHO, SERGIA. "Oncogenic KRAS: Different roles in fibroblast-induced colorectal cancer cell invasion". Trabalho apresentado em EACR-AACR-ASPIC Conference: Tumor Microenvironment, 2020.
  10. VELHO, SERGIA; Dias Carvalho, Patrícia; Ana Luísa Machado; Martins, F; Maria José Oliveira. "New aspects of KRAS-induced colorectal carcinogenesis: exploring the interaction with the tumor microenvironment". Trabalho apresentado em EACR-AACR-ASPIC Conference: Tumor Microenvironment, 2020.
  11. Martins, F; Dias Carvalho, Patrícia; Joana Carvalho; VELHO, SERGIA. "Looking to the cell surface proteome of mutant KRAS cancer cells: a 3D approach". Trabalho apresentado em EACR-AACR-ASPIC Conference: Tumor Microenvironment, 2020.
  12. Dias Carvalho, Patrícia; Martins, F; Mendonça, S; Maria José Oliveira; VELHO, SERGIA. "Oncogenic KRAS: Different roles in fibroblasts-induced colorectal cancer cell invasion". Trabalho apresentado em 8th i3S ANNUAL MEETING 2019, 2019.
  13. Machado, Ana Luísa; Carvalho, Patrícia Dias; Mendonça, S; Martins, Flávia; Oliveira, Maria José; VELHO, SERGIA. "KRAS mutation as an alert for immunotherapy in colorectal cancer". Trabalho apresentado em 3rd Symposium on Immunomodulation in Cancer and Regeneration, 2019.
  14. Carvalho, Patrícia Dias; Machado, Ana Luísa; Mendonça, S; Martins, Flávia; Carvalho, Joana; Oliveira, Maria José; VELHO, SERGIA. "The impact of KRAS oncogenic signaling on the crosstalk between colorectal cancer cells and their microenvironment". Trabalho apresentado em 26th Porto Cancer Meeting 2019- The Cancer Ecosystem: From Research to Pathology and Treatment, 2019.
  15. Mendonça, Susana; Carvalho, Patrícia Dias; VELHO, SERGIA. "The role of fibroblasts on colorectal cancer stem-like properties". Trabalho apresentado em 7th i3S annual meeting, 2018.
  16. Dias Carvalho, Patrícia; Maria Jose Oliveira; VELHO, SERGIA. "Colorectal cancer cells-fibroblasts crosstalk: KRAS matters!". Trabalho apresentado em 7th i3S Annual Meeting 2018, 2018.
  17. Dias Carvalho, Patrícia; VELHO, SERGIA. "KRAS mediates fibroblast-induced colorectal cancer cell invasion". Trabalho apresentado em 1st PhDay: From bench to stage, from desk to forum, 2018.
  18. Machado, Ana Luísa; Carvalho, Patrícia Dias; Mendonça, S; Martins, Flávia; Oliveira, Maria José; VELHO, SERGIA. "Influence of KRAS activation in the colorectal cancer immunesurveillance escape". Trabalho apresentado em 3rd Meeting of Medical Biotechnology/ 1st Iberian Congress on Medicinal Biotechnology, 2018.
  19. Ana Luísa Machado; Mendonça, S; Dias Carvalho, Patrícia; Martins, Flávia; Maria José Oliveira; VELHO, SERGIA. "Influence of KRAS activation in the colorectal cancer immunosurveillanceescape". Trabalho apresentado em 3rd ASPIC International Congress, 2018.
  20. Carlos Guimarães; Dias Carvalho, Patrícia; Flávia Castro; Martins, Flávia; Maria José Oliveira; VELHO, SERGIA. "Fibroblasts as stromal modulators of Macrophage Polarization". Trabalho apresentado em 2nd Symposium on Immunomodulation in Cancer and Regeneration, 2017.
  21. Catarina Cunha; Dias Carvalho, Patrícia; Marta Laranjeira Pinto; Ângela Margarida Costa; VELHO, SERGIA; Maria José Oliveira. "Studying the influence of K-RAS and B-RAF activation on the colorectal cancer cell-macrophage crosstalk". Trabalho apresentado em IJUP (Investigação Jovem na Universidade do Porto), 2017.
  22. Carvalho, P.D.; VELHO, SERGIA. "Mutant KRAS mediates fibroblast-induced colorectal cancer cell invasion". Trabalho apresentado em 2nd RAS Initiative Symposium, 2017.
  23. Dias Carvalho, Patrícia; André Roma; Bárbara Sousa; Nuno Mendes; Seruca, Raquel; VELHO, SERGIA. "ITGA6 as a molecular mediator of KRAS-, BRAFand PIK3CA-induced colorectal cancer stem cell phenotype". Trabalho apresentado em 5th i3S ANNUAL MEETING 2016, 2016.
  24. André Roma; Dias Carvalho, Patrícia; Seruca, Raquel; VELHO, SERGIA. "Modulation of colorectal cancer stem cell pool by oncogenic alterations". Trabalho apresentado em IJUP (Investigação Jovem na Universidade do Porto), 2016.
  25. VELHO, SERGIA; Haigis, K.M.. "IAPs inhibition as a promising therapeutic tool for the treatment of N-RAS mutant colorectal cancer". Trabalho apresentado em MGH-Center for Cancer Research retreat, 2011.
  26. VELHO, SERGIA; Pinto, A.; Sousa, F.; Oliveira, M.J.; Seruca, R.. "MLK3 P252H mutation deregulates important colorectal cancer-associated signaling pathways". Trabalho apresentado em i3S Scientific Retreat, 2011.
  27. VELHO, SERGIA; Moutinho, C.; Cirnes, L.; Schmitt, F.; Carneiro, F.; Oliveira, C.; Seruca, R.. "KRAS, PIK3CA and BRAF mutations in colorectal cancer: triggers or targets?". Trabalho apresentado em Advanced lecture course on 'Molecular mechanisms in signal transduction and cancer', 2011.
  28. VELHO, SERGIA; Moutinho, C.; Cirnes, L.; Schmitt, F.; Carneiro, F.; Oliveira, C.; Seruca, R.. "BRAF and KRAS mutations in colorectal cancer- triggers or targets?". Trabalho apresentado em 11th SPGH Annual Meeting, 2007.
  29. VELHO, SERGIA; Oliveira, C.; Cirnes, L.; Preto, A.; Hosfra, R.; Hamelin, R.; Seruca, R.. "RASSF1A Methylation Analysis in a Series of Colorectal Cancer Cell Lines". Trabalho apresentado em XIII Oporto Cancer Meeting, 2004.
  30. VELHO, SERGIA; Olveira, C.; Domingo, E.; Preto, A.; Hosfra, R.; Hamelin, R.; Yamamoto, H.; Schwartz, Simó; Seruca, R.. "RASSF1A promoter hypermethylation and KRAS/BRAF mutations are alternative events in MSI gastrointestinal tumors". Trabalho apresentado em 8th SPGH Annual Meeting, 2004.
Pré-impressão
  1. Martins, Flávia; Machado, Ana Luísa; Ribeiro, Andreia; Oliveira, Susana Mendonça; Carvalho, Joana; Matthiesen, Rune; Backman, Vadim; Velho, Sérgia. "KRAS silencing impacts chromatin organization and transcriptional activity in colorectal cancer cells". 2024. https://doi.org/10.21203/rs.3.rs-3752760/v2.
    10.21203/rs.3.rs-3752760/v2

Outros

Outra produção
  1. Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis. 2021. Patrícia Dias Carvalho; Flávia Martins; Susana Mendonça; Andreia Ribeiro; Ana Luísa Machado; Joana Carvalho; Maria José Oliveira; Sérgia Velho. https://doi.org/10.1101/2021.11.16.468815.
    10.1101/2021.11.16.468815
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2024 Tumor-Hematopoietic Communication in Colorectal Cancer Immune Evasion The Ecology of Cancer
Champalimaud Foundation
2023 Translational research in Portugal: Current state and challenges from the researcher perspective XI Perspectives in Oncology
XI Perspectives in Oncology (Portugal)
2022 Mutant KRAS & the tumor microenvironment: It takes two to tango. Seminar at CESPU
CESPU (Portugal)
2022 Mutant KRAS elicits an intestinal-spleen immunoregulatory crosstalk during intestinal tumorigenesis Symposium on Immunomodulation in Cancer and Regeneration
Symposium on Immunomodulation in Cancer and Regeneration
2019 Molecular study advances: The impact on patients’ selection for CRT Jornadas Portuguesas de Cirurgia – Colorectal cancer pathology: a multidisciplinar approach
Fundação Cupertino de Miranda (Porto, Portugal)
2018 KRAS mediates colorectal cancer cell invasion induced by fibroblasts International Conference on Tumor Microenvironment Progression, Therapy and Prevention
The International Cancer Microenvironment Society (Lisbon, Portugal)
2017 ITGA6 as a molecular mediator of KRAS-, BRAF- and PIK3CA-induced colorectal cancer stem cell phenotype Translating Colorectal Cancer Research workshop
Cost Action BM1 206 (Porto, Portugal)
2014 How oncogenes and non-neoplastic components play together for colorectal cancer development 4th i3S Annual Meeting
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal (Póvoa de Varzim, Portugal)
2014 Medicina molecular: da investigação à prática clínica. A contribuição da investigação no tratamento do cancro colo-retal III In4Med
Universidade de Coimbra (Coimbra, Portugal)
2013 MAPK signaling activation in colorectal cancer 7th National Meeting on Cell Signalling - SINAL 2013
Universidade de Aveiro (Aveiro, Portugal)
2013 N-RAS mutations in colorectal cancer. Mechanisms of oncogenesis and therapeutic implications Colrain meeting
(Colrain, Estados Unidos)
2010 Mapk oncogenic activation in MSI gastrointestinal tumours 1st i3S Annual Meeting
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal (Póvoa de Varzim, Portugal)

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2021/01 - Atual Deciphering the role of cholesterol as a mediator of oncogenic signaling and immune regulation in colorectal cancer
Orientador de Ana Luísa Machado
 Biomedicine (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2019 - Atual Targeting HER2-positive gastric and esophageal cancers with functionalized lipid nanoparticles of docetaxel: development and characterization of thermosensitive in situ gels for intratumoral drug delivery
Coorientador de Ana Camila Gomes Marques
 Pharmaceutical Sciences (Doutoramento)
Universidade do Porto Faculdade de Farmácia, Portugal
2023/09/01 - 2024/12/13 Unveiling the role of cholesterol in the colorectal cancer microenvironment
Orientador
 Master degree in Molecular Medicine and Oncology (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2020 - 2024 The role of BRAF V600E mutation and inflammation in the development of colorectal cancer
Orientador de Susana Mendonça
Biomedicine (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2020 - 2024 Identification of therapeutic targets and disease biomarkers for mutant KRAS cancer patients: fulfilling an unmet clinical need
Orientador de Flávia Martins
 Biomedicine (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2022/09/01 - 2023/07/31 Understanding the role of extracellular vesicles derived from mutant KRAS colorectal cancer cells on T-cell activation and exhaustion
Coorientador
 Master Degree in Biomedical Research (Mestrado)
2022/09/01 - 2023/07/31 Non-invasive monitoring of metastatic colorectal cancer in circulating tumor DNA and exosomal RNA
Orientador
 Master Degree in Oncology - Clinical Oncology (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022/01/01 - 2023/07/31 In silico dissection of mutant KRAS and cholesterol immunomodulatory effects
Coorientador
 Master Degree in Biostatistics and Bioinformatics Applied to Health (Mestrado)
2022/02/01 - 2022/07/31 Elucidating the mechanisms of colorectal cancer
Coorientador
 Biomedical Engineering (Mestrado)
2021/09/01 - 2022/07/31 The role of hypoxia on immunomodulation at the colon cancer microenvironment.
Coorientador
 Oncology (Mestrado)
2021/09/01 - 2022/07/31 Evaluation of the impact of 2D versus 3D cell culture systems in the communication and modulation of the tumour microenvironment
Orientador
 Oncobiology (Mestrado)
2018 - 2022 Exploring the impact of mutant kras on epithelial-fibroblasts interactions during coloraractal initiation and progression
Orientador de Patrícia Dias Carvalho
 Patologia e Genética Molecular (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020/09 - 2021/07 Deciphering the functional role of KRAS-induced SUSD2 downregulation in colorectal cancer
Orientador de Diogo Coelho
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2021 Centriole aberrations and cancer stem cells
Coorientador de Irina Suheila Martins Leal Fonseca
Graduate Programme Science for Development (Doutoramento)
Universidade Nova de Lisboa, Portugal
2020 - 2020 Identification of Biomarkers of Resistance to Immune Checkpoint Inhibitors
Orientador de Tânia Rodrigues Vieira
Biochemistry (Licenciatura/Bacharelato)
Universidade do Porto Faculdade de Ciências, Portugal
2020 - 2020 Pre-clinical evaluation of novel chemical compounds for cancer treatment: tackling unmet clinical needs
Orientador de Ana Sofia Valdeira
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
2018 - 2019 To identify the key molecular players in mediating colorectal cancer cell invasion and metastization induced by cancer-associated fibroblasts
Orientador de Flávia Martins
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
2017 - 2019 Influence of KRAS activation in the colorectal cancer immunosurveillance
Orientador de Ana Luísa Machado
 Bioquímica em Saúde (Mestrado)
Instituto Politécnico do Porto Escola Superior de Saúde, Portugal
2017 - 2019 CSC niche: the role of cellular and non-cellular components from the tumour microenvironment
Orientador de Susana Mendonça
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
2016 - 2018 To identify the key molecular players in mediating colorectal cancer cell invasion and metastization induced by cancer-associated fibroblasts
Orientador de Patrícia Dias Carvalho
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
2017 - 2017 Cancer-associated fibroblasts and tumor-associated macrophages: exploring their mutual regulation.
Orientador de Carlos Ferreira Guimarães
 Bioengenharia (Mestrado)
Universidade do Porto Faculdade de Engenharia, Portugal
2015 - 2016 Modulation of colorectal cancer stem cell pool and its crosstalk with tumor microenvironment by KRas, BRaf, and PIK3CA mutations
Orientador de André Emanuel Serra Roma
Investigação Biomédica (Mestrado)
Universidade de Coimbra, Portugal
2014 - 2014 Characterization of the expression of intestinal homeostasis-related signaling pathways in KRAS mutant colorectal cancer cell lines
Orientador de Anjali Balgobind
Van Hall Larenstein University of Applied Sciences, Países Baixos
2009 - 2010 Cellular effects of MLK3 mutations
Coorientador de Ana Teresa Ferreira Correia Pinto
Universidade de Coimbra, Portugal
2007 - 2009 MLK3, a new cancer-related gene and its associated target molecules
Coorientador de Filipa Sousa
Universidade do Porto, Portugal

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2024/10/10 - 2025/10/11 Together with Prof. Nuno Rodrigues dos Santos (i3S), I am organizing the SINAL conference. The SINAL meeting has served as a catalyst for dialogue and interdisciplinary collaboration among researchers dedicated to key questions in cell biology and signal transduction, with profound implications for the understanding and treatment of numerous human diseases. Over its various editions, SINAL has distinguished itself as a premier forum for innovative presentations, dynamic discussions, and valuable networking opportunities. (2025/10/10 - 2025/10/11)
Congresso (Membro da Comissão Organizadora)
 Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2018 - 2018 Technology transfer and entrepreneurship program HiTech Program 2018 Ed.
HiSeedTech, Portugal
2017 - 2017 Technology transfer and entrepreneurship program RESOLVE program, 2nd Ed.
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Júri de grau académico

Tema
Tipo de participação 		Nome do candidato (Tipo de grau)
Instituição / Organização
2024/11 Estudo da sinergia de três fármacos no tratamento do carcinoma hepatocelular
Arguente principal
 M. F. Moreira (Mestrado)
Universidade do Porto Faculdade de Farmácia, Portugal
2024/07/01 Immunomodulatory functionalized nanoparticles to improve chemotherapeutic treatment in metastatic colorectal cancer
Arguente
 Maria José Silveira (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2023/06/01 Microbiome, immune response, and cancer: A game changer triad in colorectal cancer?
Arguente principal
 Patrícia Vieira (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2023/05/01 RBPlasticity: RNA-binding proteins’ role in normal and malignant intestinal stem cell reprogramming.
Arguente principal
 Rita Silva (Doutoramento)
Universidade do Porto Faculdade de Medicina, Portugal
2023/03/01 Tumor microenvironment of colorectal cancer: Podoplanin expression in neoplastic cells and cancer-associated fibroblasts and unfavorable pathological features.
Arguente principal
 Ricella da Silva (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2020 Role of ccl18 on colorectal cancer immune modulation
Arguente principal
 Ana Manuela Canha Borges (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2020 Seeking for new p53-activating agents: effective therapies for colorectal cancer
Arguente
 Helena Isabel Nogueira Ramos Rocha (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 Mitochondrial dynamics in thyroid cancer: unravelling the role of DRP1
Arguente principal
 Sara Alexandra de Sousa Barambana (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 Identification of novel prognostic biomarkers for stage II colorectal cancer
Arguente principal
 Filipa Alexandra Mesquita Amorim (Outro)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 Role of ccl18 on colorectal cancer immune modulation
Arguente principal
 Ana Manuela Canha Borges (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2019 Targeting antigen­ presenting cells: chitosan/poly (y-glutamic acid) nanoparticles as adjuvants to anticancer therapy
Arguente
 Flávia Raquel Teixeira de Castro (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 Role of the RNA-binding protein MEX3A in intestinal carcinogenesis
Arguente principal
 Dalila de Jesus Lopes Mexieiro (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
2017/06/01 Papel de Hakai durante la progresión tumoral: Implicaciones sobre la plasticidad epitelial
Arguente
 R. C. Castosa (Doutoramento)
Fundación Universidade da Coruña, Espanha
2014 Complex cell-based model of intestinal permeability
Arguente principal
 Joana Costa (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Arbitragem científica em conferência

Nome da conferência Local da conferência
2018 - 2018 International Conference on Tumor Microenvironment, Progression, Therapy & Prevention PT Meeting Center
2018 - 2018 Cancro colorretal em Portugal: da investigação à prevenção e ao tratamento Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2019 - Atual Cells (2073-4409) MDPI

Consultoria / Parecer

Descrição da atividade Instituição / Organização
2017 - 2017 Papel de Hakai durante la progresión tumoral: implicaciones sobre la plasticidade epitelial Universidade da Coruña, Espanha

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2015 - Atual Module on Tumor Microenvironment GABBA PhD Programme Universidade do Porto Faculdade de Medicina, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Universidade do Porto Instituto de Biologia Molecular e Celular, Portugal

Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
2023/09/01 - 2024/06/30 Honorary Collaborator, Department of Anatomic Pathology, Microbiology, Preventive Medicine and Public Health and Legal Medicine and Forensics, Valladolid University (Spain), 2023-2024 and 2024-2025. BSc degree in Biomedicine and Advanced Therapies; Curricular unit: “Morpho-structural and Molecular Pathology of Human Disease”; Topic: “Molecular bases of development, clinical course, and therapeutic response of esophageal, stomach, and colon tumors”. Molecular bases of development, clinical course, and therapeutic response of esophageal, stomach, and colon tumors (Bachelor) Universidad de Valladolid, Espanha

Membro de associação

Nome da associação Tipo de participação
2024/01/01 - Atual SPI Member
2024/01/01 - Atual SPO Member
2024 - Atual EU COST action Adaptive and acquired resistance in gastrointestinal cancers-contemporary and emerging resolutions, submitted in 2024. Invited member Invited member
2016/01/01 - Atual ASPIC Member
2009/01/01 - Atual EACR Member
2018 - 2019 The Colorectal Cancer Working Group Member of the Scientific Committee

Membro de comissão

Descrição da atividade
Tipo de participação 		Instituição / Organização
2019 - 2024 Member of Maria José Silveira PhD's committee. “Immunomodulatory functionalized nanoparticles to improve chemotherapeutic treatment in metastatic colorectal cancer”
Consultor
 Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Outro júri / avaliação

Descrição da atividade Instituição / Organização
2023 - Atual PhD grant reviewer/Evaluator for BiotechHealth PhD program Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016 - Atual Grant Reviewer/Evaluator Universidade de Coimbra, Portugal
2024 - 2024 Grant reviewer/evaluator Fonds zur Förderung der wissenschaftlichen Forschung, Áustria
2023 - 2023 Grant reviewer/Evaluator World Cancer Research Fund, Reino Unido
2023 - 2023 Grant reviewer/evaluator Institute Nacional du Cancer, França
2022 - 2022 Grant reviewer/Evaluator Deutsche Forschungsgemeinschaft, Alemanha
2015 - 2019 Grant reviewer/evaluator Hrvatska zaklada za znanost, Croácia

Tutoria

Tópico Nome do aluno
2019 - 2024 Mentoring Junior Researcher (postdoctoral level) on "The role of exosomes in metastatic colorectal cancer" Joana Carvalho
2020 - 2020 Visiting MSc student from the Oncology Master Program, ICBAS, UP Diogo Coelho
2020 - 2020 Visiting PhD student from University of Sciences and Technology Houari Boumediene, Algeria. "Testing the effect of repurposing drugs for colorectal cancer therapy". Allal Badredine
2019 - 2020 Mentoring Junior Researcher (postdoctoral level) on "Pre-clinical evaluation of novel chemical compounds for cancer treatment: tackling unmet clinical needs" Andreia Ribeiro
2016 - 2016 Visiting PhD student from University of Vigo, Spain. “Metastatic functionalities of colorectal cancer cell lines are influenced by expression levels of CD26/DPP4 and partially inhibited by sitagliptin”. Marta Quiroga
Distinções

Prémio

2024 Patient Advocacy Award
Associação Portuguesa de Investigação em Cancro, Portugal
2023 Best Oral Communication
2022 Patient Advocacy Award
Associação Portuguesa de Investigação em Cancro, Portugal
2022 Best Oral Communication
2021 Assistant Researcher Contract
Fundação para a Ciência e a Tecnologia, Portugal
2020 Best Oral Presentation 2020
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal
2020 Best Oral Communication
2019 ImmunoTools special Award 2019
ImmunoTools, Alemanha
2019 Best Oral Communication
2018 Best Innovation Project Prize
RESOLVE program, Portugal
2016 EACR prize for the best poster at the 2nd International ASPIC Meeting
European Association For Cancer Research, Reino Unido
2014 Assistant Researcher Contract
Fundação para a Ciência e a Tecnologia, Portugal
2011 Post-Doctoral fellowship
Fundação para a Ciência e a Tecnologia, Portugal
2006 Doctoral fellowship
Fundação para a Ciência e a Tecnologia, Portugal